Navigation Links
Crucial Directives Must be Revised to Protect Patients' Interests and Improve Access to Treatment

BRUSSELS, September 1, 2011 /PRNewswire/ --

The current revision of two European Directives that are crucial to successful research into blood-related diseases must ensure the safety of patients and enhance their access to vitally-important treatment.

This was a key message of a two-day conference, "Haematology and the next European decade", hosted by the European Parliament and attended by doctors, researchers, parliamentarians, patients' organisations and Commission officials.

The revision of the Clinical Trials Directive, which provides the regulatory framework for the testing of new drugs on humans, has reached its final stages before a draft law is proposed by the European Commission within the next few months, but some politically-sensitive issues still remain.

There is a clear consensus among all stakeholders that the existing processes are overly bureaucratic, costly and time-consuming. "If we want to keep modern scientific research in Europe, we need to modernise our Directive", said Philippe Juvin MEP, the European Parliament's rapporteur on the revision.

However, haematological researchers and patients' organisations insist that seeking to reduce costs and simplify the rules in order to encourage more clinical testing in Europe must not compromise patient safety.

Also, the changes must aim to reverse the economic pressure on independent academic research - "squeezing academic research into a commercial strait-jacket" - and so facilitate a rich source of new treatments for blood-related diseases, especially rare forms of cancer.

As part of its aim to highlight the positive impact of haematology research across a range of medical conditions, the conference - organised jointly by the European Cancer Patient Coalition and the European Hematology Association, the haematologists' organisation - also discussed today the ongoing revision of the 2005 Directive relating to professional qualifications.

Both haematology researchers and patient organisations voiced concerns that respect for the free movement of medical professionals in Europe should not compromise standards of competence that could impact the safety and quality of patient care.

Haematology - a discipline covering all blood-related areas, from frequent diseases like anaemia to rare cancers, including malignant and non-malignant diseases - is always at the forefront of medical research.

It is literally vital for patients that any new EU legislation should improve co-operation for more and better-targeted funding for research in haematology, allowing haematologists to secure the research resources they need to help patients access the best possible expertise and treatment. The conference therefore aims to create grass-roots momentum for collaboration by all stakeholders at European, national and regional level to ensure this happens.


SOURCE European Hematology Association
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Researchers at the University of Georgia Discover Protein is Crucial to Reproduction of Parasites Involved in Disease
2. Novel use of MEMS microphones to map noise pollution and meet EU directives
3. Talecris Biotherapeutics Announces Revised Record Date and Meeting Date for Special Meeting of Shareholders
4. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
5. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
6. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
7. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
8. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
9. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
10. Trudeau Institute announces a discovery in how FluMist elicits protection
11. PPTA Praises Legislation That Protects the Treatment of Rare Diseases
Post Your Comments:
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf ... the 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green Section ... her work with turfgrass. , Clarke, of Iselin, N.J., is an extension ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
Breaking Biology Technology:
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):